This activity, and the live symposium on which it is based, were supported by an education grant from Novo Nordisk, Inc. The live symposium, "Tailoring Treatment for Type 2 Diabetes: Uncovering the HOW and NOW of GLP-1 Receptor Agonist Therapy," presented Thursday, March 17, 2011, at the American College of Osteopathic Family Physicians' (ACOFP) 48th Annual Convention & Exhibition in San Antonio, Texas, was sponsored by the ACOFP and developed by the Institute for Medical and Nursing Education.
This activity is intended for primary care physicians, osteopathic family physicians, nurses, diabetes educators and other healthcare providers (HCPs) who treat patients with type 2 diabetes mellitus (T2DM).
Scott V Joy, MD, FACP — Activity Chair
Duke Primary Care
Duke University Health System
Durham, North Carolina
Jeffrey S Freeman, DO, FACOI
Professor of Internal Medicine
Chairman, Division of Endocrinology and Metabolism
Philadelphia College of Osteopathic Medicine
James R LaSalle, DO, FAAFP
Medical Arts Research Collaborative
Excelsior Springs, Missouri
At the conclusion of this activity, participants should be able to:
- Outline the current standards of glycemic control and potential opportunities for individualized treatment of T2DM with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy
- Summarize the benefits and limitations of current GLP-1 RAs
- Assess the nonglycemic effects of GLP-1 RA therapy in patients with T2DM
- Identify key patient characteristics that support or preclude the use of GLP-1 RA therapy for T2DM
- Describe initiation strategies and potential dose adjustments for patients with comorbid conditions (eg, cardiovascular disease, renal disease, diabetic neuropathy)
This activity will feature lectures with questions through interactive online polling, whereby you can evaluate your answers against those of your colleagues. A wrap-up panel discussion led by the expert faculty will focus on current questions that are relevant to you in your clinical practice.
CME/CE Accreditation Statements:
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
IMNE designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.
IMNE designates this educational activity for 1.0 contact hours (0.10 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.
In compliance with ACCME and ANCC, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, educational partner staff, and CME/CE reviewers) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical and medical device products.
In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict have been made in the form of external peer review of educational content.
The following disclosures have been made:
Jeffrey S Freeman, DO, FACOI
Speakers Bureau: Novo Nordisk Inc; Merck & Co, Inc; GlaxoSmithKline; Boehringer Ingelheim
Consultant for Fee: Novo Nordisk Inc; Merck & Co, Inc; GlaxoSmithKline; Boehringer Ingelheim
Scott V Joy, MD, FACP
Consultant for Fee: Eli Lilly and Company.
James R LaSalle, DO, FAAFP
Speakers Bureau: AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Novo Nordisk Inc
Consultant for Fee: AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Novo Nordisk Inc.
Educational Partner Staff
IMNE staff associated with the development of this program reported the following relevant financial relationships and/or conflicts of interest:
Director, Program Development
Ms Carbonara has no relevant financial relationship to disclose.
Robin Devine, DO
Mr Devine has no relevant financial relationship to disclose.
Kimberly McFarland, PhD
Senior Medical Writer
Stock Interests: Pfizer Inc; Procter & Gamble
Angela C McIntosh, PhD
Dr McIntosh has no relevant financial relationship to disclose.
Adelfo San Valentin, MBA
Associate Director of CME
Mr San Valentin has no relevant financial relationship to disclose.
Steve Weinman, RN
Mr Weinman has no relevant financial relationship to disclose.
Dr Joy chaired the live symposium on which this article is based, developed the content for this manuscript, and resolved conflicting information from the faculty.
Dr Freeman lectured in the live symposium and developed the content for this manuscript.
Dr LaSalle lectured in the live symposium and developed the content for this manuscript.
The authors thank Robin Devine, DO; Kimberly McFarland, PhD; and Angela C McIntosh, PhD for editorial assistance with the manuscript.
This activity is designed for the educational purposes of HCPs. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.
While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Commercial Support Acknowledgment:
This activity is supported by an educational grant from Novo Nordisk Inc.
Method of Participation:
To obtain CME credit, each participant should:
- View the content presented
- Answer all questions posed throughout the activity
- Complete and submit the CME demographic and evaluation form
- Print the online CME certificate
This activity should take approximately 1.5 hours to complete. The expiration date for this activity is September 6, 2012. No credit will be granted after this date.
Minimum System Requirements:
The following system requirements are recommended for the best presentation viewing experience:
- Microsoft Windows 2000, Windows XP, Windows 2003, Windows Vista, or Macintosh OS X
- Display resolution of 800 x 600 pixels or greater
- Windows-compatible sound card
- Microsoft Internet Explorer 6.0 SP1.
- Windows Media Player 9.0
- Broadband Internet connection (256 Kbps & above)
For a complete list of system requirements needed to view the webcast please click here (this link opens a pdf document). If you have any questions about viewing the webcast please contact us.
Date of Original Release: Friday, February 5, 2010 (satellite symposium)
Release Date: May 2010
Expiration Date: May 31, 2011
Estimated Time to Complete this Activity: 1.5 hours
Sponsored by The Institute for Medical and Nursing Education, Inc.
Supported by an educational grant from Novo Nordisk Inc.